Get startedLog in
    Picture of Elicera Therapeutics AB logo

    ELIC — Elicera Therapeutics AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Elicera Therapeutics Provides Update On CARMA Study

    Picture of Elicera Therapeutics AB logoElicera Therapeutics AB
    06/03/2026 08:00
    March 6 (Reuters) - Elicera Therapeutics AB ELIC.ST:

COMPLETE METABOLIC RESPONSE (CMR) AND WELL TOLERATED TREATMENT IN FIRST TWO PATIENTS OF COHORT 3 IN CARMA STUDY

ACROSS 8 PATIENTS TREATED TO DATE: DISEASE CONTROL RATE: 100%, OVERALL RESPONSE RATE (ORR): 7/8, CMR AT MONTH 1: 6/8

Source text: ID:nWkr5RDLt4

Further company coverage: ELIC.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Elicera Therapeutics AB

    See all news